PL1699915T3 - Zastosowanie erytropoetyny do regeneracji tkanki wątrobowej - Google Patents

Zastosowanie erytropoetyny do regeneracji tkanki wątrobowej

Info

Publication number
PL1699915T3
PL1699915T3 PL04804424T PL04804424T PL1699915T3 PL 1699915 T3 PL1699915 T3 PL 1699915T3 PL 04804424 T PL04804424 T PL 04804424T PL 04804424 T PL04804424 T PL 04804424T PL 1699915 T3 PL1699915 T3 PL 1699915T3
Authority
PL
Poland
Prior art keywords
epo
liver
tissue
days
erythropoietin
Prior art date
Application number
PL04804424T
Other languages
English (en)
Inventor
Augustinus Bader
Original Assignee
Augustinus Bader
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP03029961A external-priority patent/EP1550715A1/de
Priority claimed from DE10361813A external-priority patent/DE10361813A1/de
Application filed by Augustinus Bader filed Critical Augustinus Bader
Publication of PL1699915T3 publication Critical patent/PL1699915T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1816—Erythropoietin [EPO]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/37—Digestive system
    • A61K35/407—Liver; Hepatocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/196—Thrombopoietin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
    • A61L27/38—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells
    • A61L27/3804—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells characterised by specific cells or progenitors thereof, e.g. fibroblasts, connective tissue cells, kidney cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L27/54—Biologically active materials, e.g. therapeutic substances
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/04—Drugs for disorders of the respiratory system for throat disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/14—Drugs for genital or sexual disorders; Contraceptives for lactation disorders, e.g. galactorrhoea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
    • A61L2300/412—Tissue-regenerating or healing or proliferative agents
    • A61L2300/414—Growth factors

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • Transplantation (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Reproductive Health (AREA)
  • Pulmonology (AREA)
  • Physiology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Otolaryngology (AREA)
  • Molecular Biology (AREA)
  • Cardiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Heart & Thoracic Surgery (AREA)
PL04804424T 2003-12-30 2004-12-30 Zastosowanie erytropoetyny do regeneracji tkanki wątrobowej PL1699915T3 (pl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP03029961A EP1550715A1 (de) 2003-12-30 2003-12-30 Verfahren zur Regenation von Gewebe
DE10361813A DE10361813A1 (de) 2003-12-30 2003-12-30 Verfahren zur Regeneration von Gewebe
EP04804424A EP1699915B1 (de) 2003-12-30 2004-12-30 Verwendung des erythropoietins zur regeneration von lebergewebe
PCT/EP2004/014839 WO2005063965A1 (de) 2003-12-30 2004-12-30 Verfahren zur regeneration von gewebe

Publications (1)

Publication Number Publication Date
PL1699915T3 true PL1699915T3 (pl) 2010-11-30

Family

ID=34740522

Family Applications (2)

Application Number Title Priority Date Filing Date
PL10005293T PL2233150T3 (pl) 2003-12-30 2004-12-30 Erytropoetyna do zastosowania w leczeniu ran lub transplantacji komórek
PL04804424T PL1699915T3 (pl) 2003-12-30 2004-12-30 Zastosowanie erytropoetyny do regeneracji tkanki wątrobowej

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PL10005293T PL2233150T3 (pl) 2003-12-30 2004-12-30 Erytropoetyna do zastosowania w leczeniu ran lub transplantacji komórek

Country Status (14)

Country Link
US (2) US7910547B2 (pl)
EP (2) EP1699915B1 (pl)
JP (2) JP4903580B2 (pl)
AT (1) ATE469654T1 (pl)
AU (2) AU2004309083B2 (pl)
BR (1) BRPI0418326A (pl)
CA (1) CA2550301A1 (pl)
DE (1) DE502004011252D1 (pl)
DK (2) DK2233150T3 (pl)
ES (2) ES2346226T3 (pl)
PL (2) PL2233150T3 (pl)
PT (1) PT1699915E (pl)
RU (2) RU2392314C2 (pl)
WO (1) WO2005063965A1 (pl)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10026480A1 (de) * 2000-05-29 2001-12-13 Augustinus Bader Verfahren zur Herstellung eines empfängerspezifischen Gewebe-Transplantats oder -Implantats
PT1699915E (pt) * 2003-12-30 2010-08-31 Augustinus Bader Utilização de eritropoietina para a regeneração de tecido hepático
JP4982841B2 (ja) * 2005-10-12 2012-07-25 国立大学法人名古屋大学 再生医療骨組成物
US20080107632A1 (en) * 2006-09-06 2008-05-08 Henrich Cheng Fibrin glue composition for repairing nerve damage and methods thereof
JP4696247B2 (ja) * 2006-12-11 2011-06-08 国立大学法人 筑波大学 肝線維化抑制剤
JP5098018B2 (ja) * 2007-03-06 2012-12-12 国立大学法人 筑波大学 肝炎治療剤
AR065613A1 (es) * 2007-03-09 2009-06-17 Chugai Pharmaceutical Co Ltd Agentes de proteccion para organos transplantados
EP2018835B1 (de) 2007-07-09 2014-03-05 Augustinus Bader Wirkstoff abgebendes Pflaster
WO2009022338A2 (en) 2007-08-16 2009-02-19 Saher Hamed Erythropoietin and fibronectin compositions for therapeutic and cosmetic applications
CN101951944B (zh) 2007-12-28 2015-04-01 奥古斯蒂努斯·巴德 用于皮肤创伤愈合的红细胞生成素的局部施用和配制剂
US9855370B2 (en) 2008-01-08 2018-01-02 Yale University Compositions and methods for promoting patency of vascular grafts
WO2009093240A2 (en) * 2008-01-24 2009-07-30 Ademex Ltd. Erythropoietin and fibronectin compositions for bone regeneration
US8470369B2 (en) * 2008-03-10 2013-06-25 Marfly 2, L.P Bone paste composition
CA2719437A1 (en) * 2008-03-31 2009-10-08 Augustinus Bader Method and composition for the regeneration of tissue with the aid of stem cells or bone-marrow cells
WO2010072417A2 (en) * 2008-12-24 2010-07-01 Augustinus Bader Rapid preparation and use of engineered tissue and scaffolds as individual implants
US20100272816A1 (en) * 2009-04-27 2010-10-28 Wolfgang Rudinger Microcapsules comprising liver cells and erythropoietin, methods for preparing said microcapsules and methods for treating a patient comprising applying said microcapsules to the patient
WO2011102991A1 (en) * 2010-02-22 2011-08-25 President And Fellows Of Harvard College Methods of generating engineered innervated tissue and uses thereof
EP2539443B1 (en) * 2010-02-23 2019-03-27 Sebana Medical Ltd. Erythropoietin for use in enhancing fat graft survival
WO2011153512A2 (en) 2010-06-03 2011-12-08 Indiana University Research And Technology Corporation Use of compounds with thrombopoietic activity to promote bone growth and healing
EP2590666B1 (en) 2010-07-06 2017-04-26 Augustinus Bader Topical application of erythropoietin for use in the treatment of injuries of the cornea
WO2012031778A1 (de) 2010-09-12 2012-03-15 Augustinus Bader Verwendung von erythropoietin bei der heilung von wunden oder gewebedefekten ohne narbenbildung
US9956265B2 (en) 2011-04-26 2018-05-01 Ajou University Industry-Academic Cooperation Foundation Composition for aiding surgical procedures for treating ischemic vascular diseases
US11311367B2 (en) 2012-01-31 2022-04-26 Wake Forest University Health Sciences Tissue-engineered gut-sphincter complexes and methods of making the same
WO2013116479A1 (en) * 2012-01-31 2013-08-08 Wake Forest University Health Sciences Innervation of engineered structures
WO2017117229A1 (en) 2015-12-30 2017-07-06 Wake Forest University Health Sciences Tissue-engineered gut-sphincter complexes and methods of making the same
EP3712612A1 (en) 2013-01-03 2020-09-23 Brigham and Women's Hospital, Inc. System and method for producing target biological substances
RU2522816C1 (ru) * 2013-02-12 2014-07-20 Российская Федерация, от имени которой выступает Министерство промышленности и торговли Российской Федерации (Минпромторг России) Композиция для клеточно-заместительной терапии дефектов мягких тканей
US10590373B2 (en) 2014-03-31 2020-03-17 Brigham And Women's Hospital, Inc. Systems and methods for biomimetic fluid processing
JP2016067312A (ja) * 2014-09-30 2016-05-09 株式会社ジーシー 軟骨分化培養液、及び軟骨組織
RU2582948C1 (ru) * 2014-10-23 2016-04-27 Ренат Рашитович Ахмеров Способ волюмизации мягких тканей с помощью термически обработанной тромбоцитарной аутологичной плазмы
US10232048B1 (en) * 2014-11-18 2019-03-19 Divine Api-Logics, LLC Apitherapy method and composition
EP3359200B1 (en) * 2015-10-05 2023-08-02 Board of Regents, The University of Texas System Micro-and nano-device for cartilage injury detection and treatment
EP3386556A4 (en) 2015-12-11 2019-07-31 Research Institute at Nationwide Children's Hospital SYSTEMS AND METHOD FOR OPTIMIZED PATIENT-SPECIFIC TISSUE-RENEWED TISSUE TRANSPLANTS
EP3391887A4 (en) * 2015-12-16 2019-08-21 Daiichi Sankyo Company, Limited WOUND TREATMENT AGENT
RU2638796C1 (ru) * 2016-08-05 2017-12-15 Общество с ограниченной ответственностью "Покровский банк стволовых клеток" Способ получения двухкомпонентного препарата для лечения повреждения суставов путем малоинвазивного введения в суставную сумку и препарат, полученный этим способом
BR112019009246B1 (pt) 2016-11-10 2023-01-17 Asc Regenity Ltd Formulações cosméticas contendo moléculas derivadas de eritropoietina, polipeptídeo isolado e uso do mesmo
RU2648869C1 (ru) * 2017-04-03 2018-03-28 Анатолий Владимирович Толстов Способ лечения локальных ожоговых ран II-III А степени
RU2650214C1 (ru) * 2017-04-04 2018-04-11 федеральное государственное бюджетное образовательное учреждение высшего образования "Омский государственный медицинский университет" Министерства здравоохранения Российской Федерации (ФГБОУ ВО ОмГМУ Минздрава России) Способ комбинированной остеопластической хирургии околоносовых пазух с использованием фактора роста
RU2666595C1 (ru) * 2017-09-26 2018-09-11 федеральное государственное бюджетное образовательное учреждение высшего образования Кубанский государственный медицинский университет Министерства Здравоохранения Российской Федерации ФГБОУ ВО КубГМУ Минздрава России Гидрогель для коррекции посттрепанационного дефекта черепа
EP3768222A4 (en) * 2018-03-20 2021-12-22 University of Pittsburgh - Of the Commonwealth System of Higher Education Regenerating vital gums
US20210106718A1 (en) * 2019-10-14 2021-04-15 Board Of Regents, The University Of Texas System Mussel inspired nancomposite adhesives for biomedical applications
CN113521049A (zh) * 2021-07-29 2021-10-22 姚雷利 一种妊娠纹脱模修复方法
WO2023168153A1 (en) * 2022-03-03 2023-09-07 Fibrobiologics, Inc. Therapeutic use of fibroblasts to stimulate regeneration and repair of atrophied spleen
WO2023210713A1 (ja) * 2022-04-27 2023-11-02 国立大学法人京都大学 心外膜細胞再生促進剤および心外膜細胞の再生促進方法

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ210501A (en) 1983-12-13 1991-08-27 Kirin Amgen Inc Erythropoietin produced by procaryotic or eucaryotic expression of an exogenous dna sequence
IL77081A (en) 1984-12-04 1999-10-28 Genetics Inst AND sequence encoding human erythropoietin, a process for its preparation and a pharmacological preparation of human erythropoietin
US4677195A (en) 1985-01-11 1987-06-30 Genetics Institute, Inc. Method for the purification of erythropoietin and erythropoietin compositions
US4954437A (en) 1986-09-15 1990-09-04 Integrated Genetics, Inc. Cell encoding recombinant human erythropoietin
US5716644A (en) * 1992-06-11 1998-02-10 Alkermes, Inc. Composition for sustained release of non-aggregated erythropoietin
US6008047A (en) 1993-04-08 1999-12-28 Livercell L.L.C. Cell culturing method and medium
IL192290A0 (en) 1993-08-17 2008-12-29 Kirin Amgen Inc Erythropoietin analogs
ATE354377T1 (de) * 1993-12-02 2007-03-15 Max Delbrueck Centrum Antitumormittel, enthaltend ein zytostatikum und ein kontrastmittel
EP0745125A1 (en) 1994-02-14 1996-12-04 ZymoGenetics, Inc. Hematopoietic protein and materials and methods for making it
WO1995021919A2 (en) 1994-02-14 1995-08-17 Kirin Brewery Company, Limited Protein having tpo activity
CA2167090C (en) 1994-03-31 2002-05-14 Timothy D. Bartley Compositions and methods for stimulating megakaryocyte growth and differentiation
US7008634B2 (en) * 1995-03-03 2006-03-07 Massachusetts Institute Of Technology Cell growth substrates with tethered cell growth effector molecules
US5879673A (en) 1996-01-25 1999-03-09 Genentech, Inc. Administration of thrombopoietin on a single day only
US5817343A (en) * 1996-05-14 1998-10-06 Alkermes, Inc. Method for fabricating polymer-based controlled-release devices
RU2115748C1 (ru) * 1996-11-19 1998-07-20 Открытое акционерное общество "АВИСМА титано-магниевый комбинат" Способ переработки отходящих газов магниевого производства
WO1999000152A2 (de) 1997-06-27 1999-01-07 Augustinus Bader Bioartifizielles transplantat und verfahren zu seiner herstellung
US6165783A (en) * 1997-10-24 2000-12-26 Neuro Spheres Holdings Ltd. Erythropoietin-mediated neurogenesis
US6776984B1 (en) * 1999-08-20 2004-08-17 George R. Schwartz Induced regeneration and repair of damaged neurons and nerve axon myelin
PE20010288A1 (es) 1999-07-02 2001-03-07 Hoffmann La Roche Derivados de eritropoyetina
WO2001005955A2 (en) * 1999-07-14 2001-01-25 The Board Of Trustees Of The Leland Stanford Junior University Animals comprising human hepatocellular tissue
US6555374B1 (en) 1999-08-19 2003-04-29 Artecel Sciences, Inc. Multiple mesodermal lineage differentiation potentials for adipose tissue-derived stromal cells and uses thereof
US6479064B1 (en) * 1999-12-29 2002-11-12 Children's Medical Center Corporation Culturing different cell populations on a decellularized natural biostructure for organ reconstruction
US6586398B1 (en) 2000-04-07 2003-07-01 Amgen, Inc. Chemically modified novel erythropoietin stimulating protein compositions and methods
DE10034583A1 (de) 2000-07-14 2002-01-31 Axel Haverich Individuelle Venenklappenprothese
ES2320101T3 (es) * 2000-10-16 2009-05-19 Chugai Seiyaku Kabushiki Kaisha Eritropoyetina conjugada con mono-peg.
DE60144439D1 (de) 2000-12-20 2011-05-26 Hoffmann La Roche Konjugate von erythropoietin (epo) mit polyethylenglykol (peg)
US7767643B2 (en) * 2000-12-29 2010-08-03 The Kenneth S. Warren Institute, Inc. Protection, restoration, and enhancement of erythropoietin-responsive cells, tissues and organs
US20020187936A1 (en) * 2001-05-17 2002-12-12 Board Of Trustees For The University Of Illinois Methods of treating liver disease and liver damage with growth hormone and foxM1B
CA2449978A1 (en) * 2001-06-15 2002-12-27 Johns Hopkins Singapore Pte Ltd Biofunctional fibers
CN1294996C (zh) * 2001-11-16 2007-01-17 儿童医疗中心有限公司 组织改造雌性生殖器官的建造
JP5144876B2 (ja) * 2002-06-20 2013-02-13 バーダー、アウグスティヌス 増殖因子を用いて、および生物学的マトリクスあるいは支持構造を用いて細胞を増殖および分化する方法およびデバイス
DE10234192B4 (de) * 2002-07-26 2009-11-26 Epoplus Gmbh Co.Kg Verwendung von Erythropoetin
NZ541122A (en) * 2002-12-26 2008-09-26 Mountain View Pharmaceuticals Polymer conjugates of cytokines, chemokines, growth factors, polypeptide hormones and antagonists thereof with preserved receptor-binding activity
DE10303584A1 (de) * 2003-01-30 2004-08-12 Stauss, Robert, Dr. Verwendung von Erythropoietin (EPO) als ein Beschichtungsmaterial auf medizinischen Implantaten
PT1699915E (pt) * 2003-12-30 2010-08-31 Augustinus Bader Utilização de eritropoietina para a regeneração de tecido hepático

Also Published As

Publication number Publication date
RU2006120458A (ru) 2008-02-10
US20110172150A1 (en) 2011-07-14
EP2233150A2 (de) 2010-09-29
JP2012067117A (ja) 2012-04-05
RU2542391C2 (ru) 2015-02-20
EP1699915B1 (de) 2010-06-02
EP1699915A1 (de) 2006-09-13
JP2007517001A (ja) 2007-06-28
AU2004309083A1 (en) 2005-07-14
DK2233150T3 (en) 2016-12-12
JP4903580B2 (ja) 2012-03-28
PT1699915E (pt) 2010-08-31
DK1699915T3 (da) 2010-09-13
ES2606068T3 (es) 2017-03-17
DE502004011252D1 (de) 2010-07-15
US7910547B2 (en) 2011-03-22
AU2011200538A1 (en) 2011-03-03
EP2233150A3 (de) 2013-01-09
RU2010105646A (ru) 2011-08-27
AU2011200538B2 (en) 2012-02-23
ATE469654T1 (de) 2010-06-15
BRPI0418326A (pt) 2007-05-02
PL2233150T3 (pl) 2017-06-30
ES2346226T3 (es) 2010-10-13
AU2004309083B2 (en) 2010-11-11
WO2005063965A1 (de) 2005-07-14
RU2392314C2 (ru) 2010-06-20
CA2550301A1 (en) 2005-07-14
EP2233150B1 (de) 2016-09-07
US20080031850A1 (en) 2008-02-07

Similar Documents

Publication Publication Date Title
PL1699915T3 (pl) Zastosowanie erytropoetyny do regeneracji tkanki wątrobowej
ES2351875T3 (es) Utilización de inhibidores de las lisil oxidasas para el cultivo celular y la ingeniería tisular.
CA2323073A1 (en) Uses for human non-autologous mesenchymal stem cells
AU8476698A (en) Human mesenchymal stem cells from peripheral blood
SI1400252T1 (sl) Postopki in sestavki za zdravljenje in popravilo sklepnega hrustanca
JPS59192364A (ja) 軟骨および骨の修復方法
EP1077254A3 (en) Multiple mesodermal lineage differentiation potentials for adipose tissue-derived stromal cells and uses thereof
NZ517772A (en) Cytotoxic agents comprising taxanes and their therapeutic use
CA2387542A1 (en) Supernatant from mesenchymal stem cells for prevention and treatment of immune responses in transplantation
DE60044793D1 (de) In-vitro Herstellung von transplantierbarem Knorpelgewebe
AU5283890A (en) Fibroblast growth factor (fgf)-based stabilized compositions
WO2001068828A3 (en) Compositions and methods for regulated protein expression in gut
NO924323L (no) Nye hybridtransformerende vekstfaktorer
EP1405906A4 (en) SCHWANN CELLS FROM INTERSTITIAL MYELOID CELLS
WO1994006449A3 (en) Morphogen-induced liver regeneration
IL144523A0 (en) Method and compositions for healing and repair of articular cartilage
PT941329E (pt) Metodo para prevenir a rejeicao de enxertos em transplantacao e para produzir uma celula-hospedeiro para terapia genetica universal utilizando activacao de linfocitos (lag-3)
ATE359798T1 (de) Verwendungvon dextransulfat zur behandlung von ibmir
Ribeiro et al. Tissue engineering in plastic surgery-what has been done
Malakhov et al. Preliminary report of the clinical use of cultured allogeneic keratinocytes
AU9264198A (en) Method for producing contrast agents largely free of side-effects
UA10281C2 (uk) Спосіб отримання речовини для лікування захворювань підшлункової залози